XML 21 R6.htm IDEA: XBRL DOCUMENT v3.21.1
Consolidated Statements of Cash Flows - USD ($)
 12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Cash flows from operating activities      
Net loss $ (9,325,273) $ (8,307,965)  
Adjustments to reconcile net loss to net cash used in operating activities:      
Stock-based compensation expense 1,651,893 1,171,079  
Amortization of held-to-maturity securities, net 331,277 198,208  
Unrealized gain from investment in Alphazyme (284,709) 0  
Foreign currency exchange loss (gain), net 62,345 27,725  
Changes in operating assets and liabilities:      
Interest receivable 217,464 (35,471)  
Accounts receivable 363,365 (252,772)  
Income tax receivable 500,616 506,866  
Prepaid research and development 0 253,446  
Prepaid expenses and other current assets (2,410) (105,707)  
Accounts payable (53,200) 657,658  
Accrued expenses (80,132) 166,399  
Deferred research and development obligations 44,372 (62,358)  
Net cash used in operating activities (6,574,392) (5,782,892)  
Cash flows from investing activities      
Purchases of held-to-maturity investment securities (17,638,947) (47,615,550)  
Proceeds from maturities of investment securities 39,761,000 55,323,000  
Net cash provided by investing activities 22,122,053 7,707,450  
Cash flows from financing activities      
Proceeds from exercise of options 255,470 550,188  
Net cash provided by (used in) financing activities 255,470 550,188  
Effect of exchange rate changes on cash 10,370 (37,516)  
Net decrease in cash and cash equivalents 15,813,501 2,437,230  
Cash and cash equivalents at beginning of period 4,823,544 2,386,314  
Cash and cash equivalents at end of period 20,637,045 4,823,544 $ 2,386,314
Supplemental cash flow information      
Cash received from income tax refund $ 500,616 $ 506,866 $ 500,000